GCI advises Remexian Pharma on the entry of High Tide

GCI Management Consulting GmbH advised the shareholders of Remexian Pharma GmbH in connection with the sale of a majority stake to Canadian company High Tide Inc. High Tide, a leading Canadian corporation in the cannabis consumer goods and retail sector, is acquiring 51% of the shares in the Berlin-based cannabis trading company, thereby strengthening its strategic presence in the European market.

Remexian Pharma imports and distributes medical cannabis as a wholesaler and has an extensive partner network in procurement and distribution across Europe. The transaction creates the foundation for further growth for High Tide in a dynamically regulated market environment and also grants an option to acquire the remaining shares within the next five years.

“We are delighted to have accompanied our clients on this important strategic step,” says Markus Wenner, Managing Partner at GCI Management Consulting. “High Tide’s entry is a strong signal of the attractiveness of the German medical cannabis market and enables Remexian to access international resources and growth potential.”

GCI Management Consulting GmbH acted as exclusive sell-side advisor to the shareholders of Remexian Pharma in the transaction.